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Introduction {#sec1}
============

Efficient synthesis of chiral cyclic sulfamidates has attracted great attention in the past decades, owing to their versatilities working as valuable intermediates for the construction of some important organic compounds and bioactive molecules ([@bib1], [@bib91], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib39], [@bib58], [@bib63], [@bib9], [@bib90], [@bib26], [@bib20], [@bib21], [@bib4], [@bib70], [@bib64], [@bib69], [@bib76], [@bib5], [@bib6], [@bib84], [@bib2], [@bib81], [@bib16], [@bib45], [@bib56], [@bib92]). For example, ring-opening reactions of chiral cyclic sulfamidates can offer convenient and efficient access to chiral amines, amino alcohols, amino acids, and their derivatives ([@bib9], [@bib90], [@bib26], [@bib20], [@bib21], [@bib4], [@bib70], [@bib64], [@bib69], [@bib76], [@bib5], [@bib6], [@bib84], [@bib2], [@bib81], [@bib16], [@bib45], [@bib56], [@bib92]). So far the asymmetric catalytic synthetic methods of chiral cyclic sulfamidates were mainly focused on transition metal-catalyzed asymmetric intramolecular amidation of sulfamate esters ([@bib53], [@bib54], [@bib30], [@bib100], [@bib99], [@bib55], [@bib37]), additions of organoboron reagents to cyclic imines ([@bib16], [@bib18], [@bib45], [@bib56], [@bib92], [@bib71], [@bib72], [@bib60], [@bib61], [@bib89], [@bib35], [@bib86], [@bib102]), and asymmetric reduction of cyclic ketimines ([@bib87], [@bib98], [@bib42], [@bib48], [@bib49], [@bib34], [@bib57], [@bib38], [@bib78], [@bib43]).

Asymmetric catalytic hydrogenation of prochiral unsaturated compounds has emerged as a powerful and effective approach for the construction of chiral compounds, which has made tremendous progress ([@bib44], [@bib74], [@bib73], [@bib83], [@bib8], [@bib24], [@bib65], [@bib101], [@bib103], [@bib41], [@bib105], [@bib77], [@bib27], [@bib93], [@bib94], [@bib88], [@bib15], [@bib85], [@bib103]). Most of these powerful catalytic systems typically depended on scarce and precious transition metals, such as Ru, Rh, Ir, and Pd, which faced difficulties like limited resource, high cost, and environmental contamination. Therefore, it is important and necessary to devote much effort to developing cheap, earth-abundant, first-row transition metal catalytic systems. Recently, the Fe-, Co-, and Ni-catalyzed asymmetric hydrogenation of prochiral unsaturated compounds has received great attention, which shows the great potential of first-row transition metals in catalytic asymmetric (transfer) hydrogenation ([@bib67], [@bib68], [@bib19], [@bib50], [@bib51], [@bib52], [@bib7], [@bib82], [@bib106], [@bib66], [@bib28], [@bib29], [@bib47], [@bib80], [@bib59], [@bib17], [@bib33], [@bib36], [@bib25], [@bib96], [@bib97], [@bib32], [@bib95], [@bib79], [@bib31], [@bib104]). Among these catalytic methodologies, Ni-catalyzed asymmetric hydrogenation is still in early stage, and there are a few related studies at present ([@bib51], [@bib52], [@bib33], [@bib36], [@bib25], [@bib96], [@bib97], [@bib32], [@bib95], [@bib79], [@bib31], [@bib104]). In 2008 and 2009, Hamada and co-workers reported Ni-catalyzed asymmetric hydrogenation of α-amino-β-ketoester hydrochlorides and substituted aromatic α-aminoketone hydrochlorides through dynamic kinetic resolution ([@bib33], [@bib36]). In 2016, Chirik and co-workers discovered Ni-catalyzed asymmetric hydrogenation of α,β-unsaturated esters ([@bib79]). Recently, our group reported Ni-catalyzed asymmetric hydrogenation of functionalized enamides with excellent results ([@bib31], [@bib52]). Despite some progress having been made, it is still quite urgent to explore the wide range of substrate generality, high reactivity, excellent stereoselectivity, and high turnover numbers (TON) for the Ni-catalyzed asymmetric hydrogenation.

Asymmetric hydrogenation of cyclic sulfamidate imines is a direct and effective access to chiral sulfamidates. Zhou and co-workers established highly efficient Pd-catalyzed enantioselective hydrogenation of cyclic sulfamidate imines with excellent results ([@bib87]). To the best of our knowledge, there is no example about cheap transition metal Ni-catalyzed asymmetric hydrogenation of cyclic sulfamidate imines. Herein, we successfully realized the highly efficient Ni-catalyzed asymmetric hydrogenation of cyclic sulfamidate imines to afford chiral cyclic sulfamidates with high yields and excellent enantioselectivities ([Scheme 1](#sch1){ref-type="fig"}, up to 99% yield, \>99% enantiomeric excess \[ee\]), and the gram-scale hydrogenation can be easily achieved with only 0.1 mol% catalyst loading (TON = 1,000).Scheme 1Asymmetric Hydrogenation of Cyclic Sulfamidate Imines

Results {#sec2}
=======

Optimization Reaction Conditions {#sec2.1}
--------------------------------

We started initial investigation of the Ni(OAc)~2~-catalyzed asymmetric hydrogenation of model substrate 4-phenyl-5H-1,2,3-oxathiazole 2,2-dioxide **1a** to evaluate a variety of important chiral diphosphine ligands ([Figure 1](#fig1){ref-type="fig"}) under 60 atm H~2~ at 80°C in MeOH for 24 h. As shown in [Table 1](#tbl1){ref-type="table"}, full conversion and good to excellent enantioselectivities were obtained with (*S*)-Binapine and (*S*, *S*)-Ph-BPE as ligand (\>99% conversion, 86%--92% ee, [Table 1](#tbl1){ref-type="table"}, entries 1 and 4). Although high catalytic activity was achieved, very poor enantioselective control was afforded in the presence of (*R*c, *S*p)-DuanPhos and (*S*, *S*)-Me-DuPhos ([Table 1](#tbl1){ref-type="table"}, entries 2 and 3). In addition, ligands (*R, S*)-WalPhos, (*S*)-SegPhos, and (*S*)-BINAP did not work in this reaction; no reaction was observed ([Table 1](#tbl1){ref-type="table"}, entries 5--7). Therefore, (*S*, *S*)-Ph-BPE was revealed to be superior with the best enantioselectivity (\>99% conversion, 92% ee, [Table 1](#tbl1){ref-type="table"}, entry 4). To our delight, the same result can be achieved when the catalyst loading of Ni(OAc)~2~/(*S*, *S*)-Ph-BPE was decreased from 5.0 mol% to 1.0 mol% ([Table 1](#tbl1){ref-type="table"}, entry 8).Figure 1The Structure of Chiral Diphosphine LigandsTable 1Screening Ligands for Ni-Catalyzed Asymmetric Hydrogenation of 4-Phenyl-5H-1,2,3-oxathiazole 2,2-dioxide (1a)![](fx2.gif)EntryLigandConversion (%)[a](#tblfn1){ref-type="table-fn"}ee (%)[b](#tblfn2){ref-type="table-fn"}1(*S*)-Binapine\>99862(*R*c, *S*p)-DuanPhos\>99−23(*S*, *S*)-Me-DuPhos\>99−134(*S*, *S*)-Ph-BPE\>99925(*R*)-WalPhosNRNA6(*S*)-SegPhosNRNA7(*S*)-BINAPNRNA8[c](#tblfn3){ref-type="table-fn"}(*S*, *S*)-Ph-BPE\>9992[^2][^3][^4][^5][^6]

Inspired by the promising results, the Ni(OAc)~2~/(*S*, *S*)-Ph-BPE-catalyzed asymmetric hydrogenation of model substrate 4-phenyl-5H-1,2,3-oxathiazole 2,2-dioxide **1a** was carried out in different solvents. We found that moderate to high conversions and excellent enantioselectivities were obtained in several kinds of alcoholic solvents, such as MeOH, EtOH, ^*i*^PrOH, CF~3~CH~2~OH, and (CF~3~)~2~CHOH (62%--\>99% conversions, 91%--94% ee, [Table 2](#tbl2){ref-type="table"}, entries 1--5). Poor conversions and moderate to good enantioselectivities were provided in nonprotic solvents, such as tetrahydrofuran (THF), toluene, ethyl acetate, and 1,4-dioxane (7%--22% conversions, 58%--87% ee, [Table 2](#tbl2){ref-type="table"}, entries 7--10), and this reaction did not work in dichloromethane ([Table 2](#tbl2){ref-type="table"}, entry 6). Therefore, CF~3~CH~2~OH was selected as the best solvent to provide full conversion and the highest enantioselectivity (\>99% conversion, 94% ee, [Table 2](#tbl2){ref-type="table"}, entry 4).Table 2Screening Solvents for Ni-Catalyzed Asymmetric Hydrogenation of 4-Phenyl-5H-1,2,3-oxathiazole 2,2-dioxide (1a)![](fx3.gif)EntrySolventConversion (%)[a](#tblfn4){ref-type="table-fn"}ee (%)[b](#tblfn5){ref-type="table-fn"}1MeOH\>99922EtOH83913^*i*^PrOH62924CF~3~CH~2~OH\>99945(CF~3~)~2~CHOH\>99936CH~2~Cl~2~NRNA7THF17878Toluene22829Ethyl acetate1286101,4-dioxane758[^7][^8][^9][^10]

Substrate Scope Study {#sec2.2}
---------------------

After establishing the optimized reaction conditions, we sought to examine the substrate scope generality of this Ni-catalyzed asymmetric hydrogenation of cyclic sulfamidate imines. As listed in [Table 3](#tbl3){ref-type="table"}, the Ni-catalyzed asymmetric hydrogenation of a variety of aryl-substituted cyclic sulfamidate imines could proceed smoothly, affording the desired hydrogenation products (**2a-2l**) with full conversions, high yields, and excellent enantioselectivities (\>99% conversion, 94%--99% yields, 91%--\>99% ee). Diverse aryl-substituted cyclic sulfamidate imines bearing electron-donating (**1b-1f**) or electron-withdrawing (**1g-1l**) substituents worked well in this asymmetric hydrogenation. It is worth noting that the hydrogenation product **2i** is an important intermediate for the synthesis of the enantiomer of piperazinone acid, which was one of the two main molecular motifs in clinical candidate MK-3207 ([@bib62]). In addition, the position of substituted group on the phenyl ring was also investigated; whether the substituted groups are on the *ortho*-, *meta*-, or *para*-position of the phenyl ring, these asymmetric reductions proceeded efficiently with excellent results. Interestingly, cyclic sulfamidate imines with substituents in *ortho*-position on the phenyl ring (**1b**, **1e**, **1g**) can provide chiral cyclic sulfamidates (**2b**, **2e**, **2g**) with higher enantioselectivities. When the phenyl ring was replaced with 2-naphthyl group, the substrate (**1m**) performed well with 97% yield and 92% ee. Moreover, the heteroaromatic substrate (**1n**) was hydrogenated with moderate reactivity and excellent enantioselectivity (65% conversion, 55% yield, 95% ee). It is noteworthy that the alkyl substrates (**1o**-**1p**) worked smoothly in this asymmetric hydrogenation, providing the desired products (**2o**-**2p**) with good to excellent results (\>99% conversion, 96%--98% yields, and 83%--92% ee).Table 3Substrate Scope Study for Ni-Catalyzed Asymmetric Hydrogenation of Cyclic Sulfamidate Imines![](fx4.gif)[^11][^12]

Encouraged by these promising reaction results, other types of ketimines were employed in this catalytic system. As shown in [Scheme 2](#sch2){ref-type="fig"}, the acetophenone and 2,3-dihydro-1H-inden-1-one-derived *N*-sulfonyl ketimines **1q** and **1r** worked efficiently under optimized reaction conditions; the corresponding hydrogenation products **2q** and **2r** were obtained with full conversion, high yields, and excellent enantioselectivities (\>99% conversion, 96%--97% yields, 97%--\>99% ee).Scheme 2The Ni-Catalyzed Asymmetric Hydrogenation of Other N-Sulfonyl Ketimines

Synthetic Application {#sec2.3}
---------------------

The synthetic application potentiality of this Ni-catalyzed asymmetric hydrogenation was demonstrated by the gram-scale transformation. The asymmetric reduction of model substrate **1a** on the 6-mmol scale proceeded well in the presence of just 0.1 mol% catalyst loading (S/C = 1,000), affording product **2a** in 99% yield with 93% ee, which showed that our catalytic system had excellent catalytic activity ([Scheme 3](#sch3){ref-type="fig"}). In addition, \>99% ee can be easily achieved in CH~2~Cl~2~/hexane through simple crystallization.Scheme 3Gram-Scale Asymmetric Hydrogenation of 1a with High TON

To reveal the great utility of this methodology, some derivatization reactions of hydrogenation product **2a** were conducted ([Scheme 4](#sch4){ref-type="fig"}). The *tert*-butoxycarbonyl (Boc) group was easily introduced on the nitrogen atom of hydrogenation product **2a** to prepare compound **3** without loss of enantiomeric purity ([@bib42]). Also, it was treated with tetrabutylammonium fluoride to give enantioenriched β-fluoroamine **4** in 77% yield ([@bib92], [@bib72]). In addition, compound **3** went through nucleophilic attack of 4-methoxyphenol, which led to chiral amino ether **5** in 76% yield ([@bib92], [@bib72]). The hydrogenation product **2a** could also be efficiently reduced with LiAlH~4~ to generate (*S*)-phenylglycinol **6** in 87% yield and without loss of ee value (\>99% ee) ([@bib16], [@bib56]), which is the key intermediate to construct chiral cyclic carbamate Evans\' auxiliary ([@bib40]) and bisoxazoline ligand (*S*,*S*)-Ph-Box ([@bib22], [@bib23], [@bib75]).Scheme 4Synthetic Transformations of Product 2a

Discussion {#sec3}
==========

Mechanism Study {#sec3.1}
---------------

To explore the possible reaction mechanism for this Ni-catalyzed asymmetric hydrogenation, a series of isotopic labeling studies were conducted ([Scheme 5](#sch5){ref-type="fig"}). The cyclic sulfamidate imine **1a** was hydrogenated with 25 atm D~2~ in CF~3~CH~2~OH; the deuterium atom was solely added at the benzylic position and partly at the nitrogen atom of the product. In addition, this reduction was repeated in the presence of H~2~ and CF~3~CH~2~OD, and we found that the deuterium atom was just partly located at the nitrogen atom. Our hydrogenation product **2a** was dissolved and stirred in CF~3~CH~2~OD, and the deuterium atom was detected to be partly incorporated at the N-H position, which showed that proton exchange should occur in this process. These results suggested that the H atom at the benzylic position of the hydrogenation product was solely from H~2~.Scheme 5Deuterium-Labeling Experiments(A) The hydrogenation with D~2~ in CF~3~CH~2~OH.(B) The hydrogenation with H~2~ in CF~3~CH~2~OD.(C) The product **2a** stirring in CF~3~CH~2~OD.

Based on these observations and previous studies ([@bib79], [@bib31]), the possible catalytic mechanism of this transformation was presented in [Scheme 6](#sch6){ref-type="fig"}. The hydrogen was involved in heterolytic cleavage to form \[Ni\]-H intermediate (**II**) ([@bib46], [@bib3]), and it then went through ligand exchange with cyclic sulfamidate imine **1a**, followed by enantioselective conjugated addition of \[Ni\]-H to C=N bond of imine to provide intermediate (**TSIII**). Subsequent protonation by AcOH released the product **2a**. The N-H group of product **2a** has the possibility of undergoing H-exchange with CF~3~CH~2~OH (or AcOH) to generate compound **2a'**. To our delight, the deuterium-labeling experimental observations above are consistent with this possible catalytic cyclic pathway.Scheme 6Proposed Catalytic Cycle for the Ni-Catalyzed Asymmetric Hydrogenation of 1a

Conclusion {#sec3.2}
----------

In conclusion, the Ni-catalyzed asymmetric hydrogenation of cyclic sulfamidate imines was successfully realized, affording a variety of chiral cyclic sulfamidates with high yields and excellent enantioselectivities (up to 99% yield, \>99% ee, and 1,000 TON). Other types of N-sulfonyl ketimines worked well to give the corresponding hydrogenation products with full conversion, 96%--97% yields, and 97%--\>99% ee. In addition, this asymmetric methodology owned great synthetic utility through various product derivations to construct some important enantioenriched organic molecules, such as chiral β-fluoroamine, amino ether, and phenylglycinol. Moreover, a reasonable catalytic cycle was provided to reveal a possible mechanism for this Ni-catalyzed asymmetric hydrogenation based on the deuterium-labeling studies. Further investigations on the detailed mechanisms of Ni-catalyzed asymmetric hydrogenation strategy are in progress in our laboratory.

Limitations of the Study {#sec3.3}
------------------------

The six-membered cyclic sulfamidate imine was not suitable in this methodology.

Methods {#sec5}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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========================

Document S1. Transparent Methods, Figures S1--S104, and Schemes S1--S7
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[^1]: Lead Contact

[^2]: NR, no reaction; NA, not available.

[^3]: Unless otherwise noted, all reactions were carried out with a Ni(OAc)~2~/ligand/substrate **1a** (0.1 mmol) ratio of 1:1.1:20 in 1.0 mL MeOH under 60 atm H~2~ at 80°C for 24 h. The configuration of **2a** was determined by comparing the optical rotation data with those reported in the literature ([@bib87], [@bib42], [@bib48]).

[^4]: Conversion was determined by ^1^H NMR analysis.

[^5]: ee was determined by chiral high-performance liquid chromatography analysis.

[^6]: 1.0 mol% catalyst loading.

[^7]: NR, no reaction; NA, not available.

[^8]: Unless otherwise noted, all reactions were carried out with a Ni(OAc)~2~/(*S*, *S*)-Ph-BPE/substrate **1a** (0.1 mmol) ratio of 1:1.1:100 in 1.0 mL solvent under 60 atm H~2~ at 80°C for 24 h; the catalyst was pre-complexed in MeOH (0.1 mL for each reaction vial).

[^9]: Conversion was determined by ^1^H NMR analysis.

[^10]: ee was determined by chiral high-performance liquid chromatography analysis.

[^11]: Unless otherwise noted, all reactions were carried out with a Ni(OAc)~2~/(*S*, *S*)-Ph-BPE/substrate **1** (0.1 mmol) ratio of 1:1.1:100 in 1.0 mL CF~3~CH~2~OH under 60 atm H~2~ at 80°C for 24 h. Conversion was determined by ^1^H NMR analysis. Yield is isolated yield. The ee value was determined by high-performance liquid chromatography on a chiral column.

[^12]: Superscript letter 'a' indicates S/C = 20, 36 h.
